European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients : summary of the ECIL 3--2009 update
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 1196402
Author(s) Maertens, J; Marchetti, O; Herbrecht, R; Cornely, O A; Flückiger, U; Frêre, P; Gachot, B; Heinz, W J; Lass-Flörl, C; Ribaud, P; Thiebaut, A; Cordonnier, C; Third European Conference on Infections in Leukemia
Author(s) at UniBasel Flückiger, Ursula M.
Year 2011
Title European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients : summary of the ECIL 3--2009 update
Journal Bone marrow transplantation
Volume 46
Number 5
Pages / Article-Number 709-18
Keywords antifungals, neutropenia, leukemia, SCT, Candida, Aspergillus
Abstract In 2005, several groups, including the European Group for Blood and Marrow Transplantation, the European Organization for Treatment and Research of Cancer, the European Leukemia Net and the Immunocompromised Host Society created the European Conference on Infections in Leukemia (ECIL). The main goal of ECIL is to elaborate guidelines, or recommendations, for the management of infections in leukemia and stem cell transplant patients. The first sets of ECIL slides about the management of invasive fungal disease were made available on the web in 2006 and the papers were published in 2007. The third meeting of the group (ECIL 3) was held in September 2009 and the group updated its previous recommendations. The goal of this paper is to summarize the new proposals from ECIL 3, based on the results of studies published after the ECIL 2 meeting: (1) the prophylactic recommendations for hematopoietic stem cell transplant recipients were formulated differently, by splitting the neutropenic and the GVHD phases and taking into account recent data on voriconazole; (2) micafungin was introduced as an alternative drug for empirical antifungal therapy; (3) although several studies were published on preemptive antifungal approaches in neutropenic patients, the group decided not to propose any recommendation, as the only randomized study comparing an empirical versus a preemptive approach showed a significant excess of fungal disease in the preemptive group.
Publisher Nature Publishing Group
ISSN/ISBN 0268-3369
edoc-URL http://edoc.unibas.ch/dok/A6006573
Full Text on edoc No
Digital Object Identifier DOI 10.1038/bmt.2010.175
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/20661235
ISI-Number WOS:000290472500011
Document type (ISI) Journal Article
 
   

MCSS v5.8 PRO. 0.406 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
12/05/2021